Timing between public safety signals and label strengthening in targeted oncology therapies.

purposeTo examine the interval between stable public safety reporting patterns and subsequent substantive label strengthening in targeted oncology therapies, and assess comparator effects on signal onset.

methodsDailyMed label histories were linked to quarterly FDA Adverse Event Reporting System (FAERS) counts from openFDA. The primary analysis included 27 products across antibody-drug conjugates, immune checkpoint inhibitors, and tyrosine kinase inhibitors. Three predefined themes were assessed: interstitial lung disease/pneumonitis, hepatotoxicity, and dermatologic toxicity. Stable signal onset required at least three themed reports, reporting odds ratio ≥ 2, proportional reporting ratio ≥ 2, and persistence into the next quarter. Baseline and pre-signal status were recorded; post-signal changes were retained only after direct comparison with preceding usable archived versions confirmed substantive safety strengthening.

resultsThe label archive contained 52 correctly mapped product histories and 1022 archived version records. Among 81 product-theme pairs, 52 met the stable signal rule under the oncology proxy background. Twenty-four had substantive label strengthening by 31 December 2025, 23 had no qualifying event, 1 was excluded after manual review, and 4 were source-indeterminate. The median interval among retained events was 388 days (interquartile range 79-697). Sensitivity analysis identified 62 pairs stable under at least one background; among 52 stable under both backgrounds, 24 had differing detection dates.

conclusionThe timing between public reporting signals and later label strengthening can be reconstructed from pharmacovigilance and label-history records. The observed interval is a timing measure between public records and should not be interpreted as incidence, causality, or regulatory response time.